Anaplastic thyroid cancer (ATC) is a rare and rapidly fatal human cancer. Its usual treatment includes the combination of surgery, external hyperfractionated radiation therapy, and chemotherapy. These treatments permit achieving about 6–10 months of median survival. For this reason, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c‐Kit. Until now, the effect of pazopanib in primary human ATC cells (pATC) has not been reported in the literature. The aim of our study was to evaluate in vitro the antineoplastic effect of pazopanib in pATC. Surgical thyroidal tissues were collected from five patients with ATC, from thyroid biopsy at the moment of first surgical operation. An inhibition of proliferation, migration, and invasion, and an increase in apoptosis were demonstrated upon treating pATC cells with pazopanib (p < 0.05). Moreover, pazopanib was able to significantly decrease the VEGF expression in pATC cells (p < 0.05). To conclude, in this study, we demonstrate the antineoplastic activity of the antiangiogenic inhibitor, pazopanib, in human pATC in vitro.

Antineoplastic activity of pazopanib in anaplastic thyroid cancer in primary culture / Martina Ferrari, Silvia; Elia, Giusy; Ragusa, FRANCESCA MARTINA; Rosaria Paparo, Sabrina; Mazzi, Valeria; Patrizio, Armando; Piaggi, Simona; Baldini, Enke; Centanni, Marco; La Motta, Concettina; Antonelli, Alessandro; Fallahi, Poupak. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 24(2023), pp. 1-12. [10.3390/ijms24032398]

Antineoplastic activity of pazopanib in anaplastic thyroid cancer in primary culture

Francesca Ragusa;Armando Patrizio;Enke Baldini;Marco Centanni;Alessandro Antonelli
;
2023

Abstract

Anaplastic thyroid cancer (ATC) is a rare and rapidly fatal human cancer. Its usual treatment includes the combination of surgery, external hyperfractionated radiation therapy, and chemotherapy. These treatments permit achieving about 6–10 months of median survival. For this reason, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c‐Kit. Until now, the effect of pazopanib in primary human ATC cells (pATC) has not been reported in the literature. The aim of our study was to evaluate in vitro the antineoplastic effect of pazopanib in pATC. Surgical thyroidal tissues were collected from five patients with ATC, from thyroid biopsy at the moment of first surgical operation. An inhibition of proliferation, migration, and invasion, and an increase in apoptosis were demonstrated upon treating pATC cells with pazopanib (p < 0.05). Moreover, pazopanib was able to significantly decrease the VEGF expression in pATC cells (p < 0.05). To conclude, in this study, we demonstrate the antineoplastic activity of the antiangiogenic inhibitor, pazopanib, in human pATC in vitro.
2023
pazopanib; anaplastic thyroid cancer; primary cell cultures; tyrosine kinase inhibitors; proliferation; apoptosis; migration; invasion
01 Pubblicazione su rivista::01a Articolo in rivista
Antineoplastic activity of pazopanib in anaplastic thyroid cancer in primary culture / Martina Ferrari, Silvia; Elia, Giusy; Ragusa, FRANCESCA MARTINA; Rosaria Paparo, Sabrina; Mazzi, Valeria; Patrizio, Armando; Piaggi, Simona; Baldini, Enke; Centanni, Marco; La Motta, Concettina; Antonelli, Alessandro; Fallahi, Poupak. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1661-6596. - 24(2023), pp. 1-12. [10.3390/ijms24032398]
File allegati a questo prodotto
File Dimensione Formato  
Ferrari_Antineoplastic-activity_2023.pdf

accesso aperto

Note: Full text
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 445.38 kB
Formato Adobe PDF
445.38 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1671999
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact